Lung Cancer Trials Ask AI to find trials
RecruitingPhase 1NCT06476808
Official study title

A Study to Evaluate the Safety, Tolerability, and Efficacy of Escalating Doses of BMS-986463 in Participants With Select Advanced Malignant Tumors.

Study summary

The purpose of this study is to evaluate the safety, tolerability, and efficacy of escalating doses of BMS-986463 in participants with select advanced malignant tumors.

Ask AI to explain this study
Start here

Key things to know

Main goalTreatment

This describes the study’s primary purpose.

What is being studiedBMS-986463

The study team can explain what participation involves.

Who it may be forNon-small cell lung cancer (NSCLC)

These are broad labels—not an eligibility decision.

Checked against the public recordLast updated Jul 20, 2026 · Source: ClinicalTrials.gov

Is enrollment open?Recruiting

The study is currently accepting participants.

What kind of study?Phase 1

Interventional

Where is it offered?17 U.S. locations

Locations may change over time.

Who runs it?Bristol-Myers Squibb

Study sponsor

01
Study overview

What this study is about

Purpose
Treatment
Study type
Interventional
Phase
Phase 1
Sponsor
Bristol-Myers Squibb
Interventions being studied
Drug: BMS-986463
02
Explore related studies

How this study is categorized

These labels come from structured fields and exact terms in the public record.

Cancer type
Non-small cell lung cancer (NSCLC)→
03
Public criteria

Who may be able to participate

The sponsor separates these requirements into two groups. You do not need to interpret them alone—use them to guide a conversation with the study team.

Requirements people may need to meetInclusion criteria
  • Participants must have an Eastern Cooperative Oncology Group Performance Status of 0 or 1.
  • Participants must have at least 1 lesion accessible for biopsy in addition to the target lesion, from which a fresh pre treatment biopsy must be obtained.
  • Participants must have an unresectable/metastatic carcinoma.
Reasons someone may not be able to joinExclusion criteria
  • Participants must not have Leptomeningeal metastases.
  • Participants must not have concurrent malignancy (present during screening) requiring treatment or history of prior malignancy active within 2 years prior to treatment.
  • Participants must not have had any prior radiation therapy within 2 weeks prior to start of study treatment.
  • Other protocol-defined Inclusion/

Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.

04
Study sites

U.S. locations

  • USC/Norris Comprehensive Cancer CenterLos Angeles, California
  • Valkyrie Clinical TrialsLos Angeles, California
  • John Theurer Cancer Center at Hackensack University Medical CenterHackensack, New Jersey
  • Local Institution - 0045Columbus, Ohio
  • Local Institution - 0046Dallas, Texas
  • Local Institution - 0049Houston, Texas
  • BC Cancer VancouverVancouver, British Columbia
  • Princess Margaret Cancer CentreToronto, Ontario
  • Centre Hospitalier de l'Université de MontréalMontreal, Quebec
  • Jewish General HospitalMontreal, Quebec
  • Local Institution - 0036Bordeaux, Aquitaine
  • Local Institution - 0031Villejuif, Val-de-Marne

Source and freshness
Processed from ClinicalTrials.gov. Last public update: Jul 20, 2026. Always confirm current availability with the study team.

View original record ↗